Valeant extends its takeover bid for Allergan

Valeant Pharmaceuticals International has extended the expiration of its $51 billion offer to take over Allergan from Aug. 15 to the end of this year, without any new changes in the new improved conditions laid out on June 2. It made the announcement after receiving pledges from Allergan shareholders that ...

Keep reading this article by becoming a member


Enjoy unrestricted access to Eyewear Intelligence

To continue reading this article subscribe now

  • Unlimited access to our highly trusted industry insights and analysis
  • Benchmark yourself against the market and competitors
  • Find inspiration to drive your business forward
  • Stay up to date with new business models and startups

If you aren’t ready to subscribe now, you can REGISTER FOR FREE. Already an Eyewear Intelligence subscriber? Sign in here.